Parathyroid hormone (PTH) is an 84-amino-acid peptide hormone that is secreted by the
parathyroid gland. It has different administration modes in bone tissue through which it …

Osteoporosis represents the most common bone disease worldwide and results in a
significantly increased fracture risk. Extrinsic and intrinsic factors implicated in the …

Osteoporosis is a debilitating disease characterized by reduced bone mineral density and
an increased risk of fractures. This review aims to provide a comprehensive overview of, and …

New anti-osteoporotic agents have been developed, potentially enriching the therapeutic
armamentarium. Currently available osteoanabolic therapies are the parathyroid hormone …

Osteoporosis is a type of bone loss disease characterized by a reduction in bone mass and
microarchitectural deterioration of bone tissue. With the intensification of global aging, this …

Abaloparatide, a novel analog of parathyroid hormone‐related protein (PTHrP 1–34),
became in 2017 the second osteoanabolic therapy for the treatment of osteoporosis. This …

Three bone anabolic pharmaceuticals are currently approved for treatment of osteoporosis,
teriparatide (PTH (1–34)), the parathyroid hormone-related protein analog abaloparatide …

Teriparatide and abaloparatide are parathyroid hormone receptor 1 (PTHR1) analogs with
unexplained differential efficacy for the treatment of osteoporosis. Therefore, we compared …

Intermittent administration of PTH type 1 receptor (PTH1R) agonists increases bone
remodeling, with greater stimulation of bone formation relative to bone resorption causing …

Glucorticoid (GC) therapy is the commonest cause of secondary osteoporosis.
Ovariectomized rabbits receiving the GC methylprednisolone for 6 weeks exhibited relatively …